Calcitonin Gene-Related Peptide For The Reduction Of Allergen-Induced Airway Hyperresponsiveness
Tech ID: 00-14
Summary
Calcitonin gene-related peptide (CGRP) is a sensory neuropeptide which expression is reduced after allergen challenge in sensitized mice. The same mice develop eosinophilic airway inflammation and airway hyperresponsiveness (AHR). Scientists at National Jewish Health have shown that administration of CGRP to sensitized and challenged mice resulted in the normalization of AHR.
Potential Application
Treatment of AHR
State of Development
Administration of CGRP to sensitized and challenged mice resulted in the normalization of AHR.
This potential therapy for AHR was tested in phase II of clinical trials however the trial was never completed.
Publication
- Dakhama A et al. Respir Physiol Neurobiol. 2008 Jan 1;160(1):28-36. Epub 2007 Aug 10. PMID: 17884737
-
Dakhama A et al. Am J Respir Crit Care Med. 2002 Apr 15;165(8):1137-44. PMID: 11956058
Inventors
Erwin Gelfand, MD, Azzedine Dakhama, PhD (National Jewish Health) and Alain Cadieux, PhD (Universite de Sherbrooke)
Patent Status
Issued US patent #6,743,429 and International Patent Application publication #WO/2001/068118: pending in Canada and Europe, and issued in Australia (#2001249207).
The IP is owned by the National Jewish Health and the Universite de Sherbrooke.
Licensing Status
Available for licensing.
For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352
HilaireE@njhealth.org
